Because GLP-1 has a short half-life of approximately 2 minutes, GLP-1 analogues with longer half-lives have been developed and are now widely used for the treatment of type 2 diabetes mellitus and obesity (41–43). Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.